Ilyda SA (ILYDA) Fair Value & Analysis
Technology · GR · Market cap €61.1M
Fair value as of: Jun 24, 2026
Analysis
Ilyda SA (ILYDA) currently trades at €4.68, while our model-based Fair Value estimate is €6.28 — implying the stock looks roughly 34.3% undervalued today. We read business quality at 95/100 (high quality), in the Technology sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Ilyda SA engages in software development business in Greece. It offers enterprise resource planning systems, such as MegaTron ERP and Kinitron Smart ERP; Dioscourides Smart, Dioscourides Touch XPress, and Dioscourides ERP Retail System for pharmacies; MegaTron Pharma ERP for drugstores; and LIS Bio-Diagnosis for microbiological laboratories. The company also provides MegaTron DEVA for water supply/sewerage companies; PSIS Financial Management for public sector companies; PSIS Payroll & Personnel Management for legal entities; and SIS Secretariats of Educational Institutions for educational institutions. In addition, it provides software support services, such as telephone support, remote support, on-site support, and feedback support services; project design and implementation; software training services; and consultant agency services. The company was founded in 1992 and is headquartered in Athens, Greece.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Ilyda SA (ILYDA) undervalued?
What is the fair value of ILYDA?
What is the quality score of ILYDA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.